Phase 2 Trial of MLN9708 in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2017
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 04 Oct 2016 Interim results assessing efficacy and toxicity of two different doses of ixazomib 4 mg and 5.5mg given weekly with dexamethosone (n=70), published in the Blood Journal.
- 04 Oct 2016 Interim results (n=70) published in the Blood.